Primary diffuse large B cell lymphoma of nasal cavity and paranasal sinus in 30 cases

Shu TIAN,Wei-fang WANG,Gang YANG,Li-fen ZOU,Wei YUAN,Hai-yan ZHANG,Sheng-zi WANG,Hao DING
DOI: https://doi.org/10.14166/j.issn.1671-2420.2017.03.005
2017-01-01
Abstract:Objective To investigate the clinical features and treatment strategies of primary diffuse large B cell lymphoma (DLBCL) of nasal cavity and paranasal sinuses.Methods The clinical features and prognostic factors of 30 patients who were newly diagnosed as primary DLBCL of nasal cavity and paranasal sinuses from January 2007 to December 2014 were retrospectively analyzed.Results Among 30 patients,21 cases were male and 9 were female;the median age was 63 years;26 patients were Ann Arbor stage Ⅰ,4 patients were stage Ⅱ,none presented with B symptoms.All patients received chemotherapy and radiotherapy;8 patients received R-CHOP and 22 patients received CHOP-like-based chemotherapy regimens with a median of 4 cycles.Patients were treated with three-dimensional conformal radiotherapy with a dose of 36 ~54 Gy(median dose of 46.8 Gy).One patient received central nervous system(CNS) prophylaxis during the treatment.There were 22 patients in complete remission,6 in partial remission,one in progressive disease,and one died of upper gastrointestinal hemorrhage during radiotherapy.With a median follow-up of 72 months,the 5-year survival rate was 56.7% (95% CI:47.7% to 65.7%) and two CNS relapses occurred.Conclusions Patients with primary DLBCL of nasal cavity and paranasal sinuses commonly present with localized disease but have a poor prognosis.At present,R-CHOP chemotherapy regimen is mainly used for the treatment of the disease and local radiotherapy also has an important role.CNS prophylaxis should not be routinely used in these patients.
What problem does this paper attempt to address?